Metabolic Solutions Development Company Awarded Funding by The Michael J. Fox Foundation

First-in-class mTOT Modulator™ to be studied as potential treatment for dyskinesia in collaboration with researchers at Van Andel Institute

KALAMAZOO, Mich., Feb. 7, 2013 - Metabolic Solutions Development Company, LLC (MSDC) announced today that it has received an award from The Michael J. Fox Foundation for Parkinson's Research (MJFF) to conduct preclinical research on a first-in-class mTOT Modulator, MSDC-0160, as a potential treatment for levodopa induced dyskinesia (LID). The study will be undertaken in collaboration with Patrik Brundin, MD, PhD, of Van Andel Institute (VAI). The aim of the study, titled "Potential of Novel Insulin Sensitizers to Treat Dyskinesia," is to determine if MSDC-0160 can prevent or reverse LID in a preclinical model of Parkinson’s disease (PD). Should the results show that MSDC-0160 can significantly modify LID in vivo, MSDC plans to begin a clinical trial to examine the effects of MSDC-0160 in PD patients with LID. Such a clinical trial could begin in 2014.

Date: February 7, 2013
Source: Metabolic Solutions Development Company

Return View Main Newsroom

Send to a friend Send to a friend | Print story Print Story | RSS Feed Subscribe to RSS feed